NeoGenomics (NEO) on Monday said for the fourth quarter of 2025, it expects to report total revenue of approximately $190 ...

Fort Myers-based cancer testing and research lab NeoGenomics expects to report double-digit revenue growth for 2025. However, ...

NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. I ...

NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter: In the last 3 months, 4 analysts have offered 12-month price targets for NeoGenomics. The company has an ...

NeoGenomics appointed Abhishek Jain to the role of chief financial officer, succeeding Jeff Sherman, who is set to retire from the position in March.

Management raised full-year 2025 revenue guidance to $747 million-$759 million, reflecting 13%-15% growth. Adjusted EBITDA guidance remains unchanged at $55 million-$58 million. Pathline is projected ...

CEO Chris Smith highlighted strong financial performance, with Q4 revenue reaching $172 million, marking nine consecutive quarters of double-digit growth. He also announced his retirement effective ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries: NeoGenomics has cleared ...

FORT MYERS, Fla., December 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...